{"id":1728,"date":"2018-08-23T18:34:27","date_gmt":"2018-08-23T18:34:27","guid":{"rendered":"https:\/\/fehv.org\/?p=1728"},"modified":"2018-08-23T18:34:54","modified_gmt":"2018-08-23T18:34:54","slug":"efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis","status":"publish","type":"post","link":"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/","title":{"rendered":"Efficacy of Immunotherapy with TG4040 in Chronic Hepatitis"},"content":{"rendered":"<p>In this way, the efficacy, safety and immunotherapeutic properties of TG4040 are determined in combination with interferon-pegylated (PEG) and ribavirin (R). The results of the study have been published in the journal Gastroeneterology.<\/p>\n<p>We included patients with genotype 1, not previously treated and assigned to the following groups: PEG + R for 48 weeks (Group A, N = 31 patients); PEG + R for 4 weeks followed by PEG + R 44 weeks and 6 injections of TG4040 (Group B, N = 63); and TG4040 for 12 weeks (7 injections) followed by PEG + R for 48 weeks together with 6 more injections of TG4040 (Group C, N = 59). In group C, 64% of patients had a response at the end of treatment, compared to 30% in Group A and 45.9% in Group B. Also, the sustained response in Group C was greater than in A and B (58.2%, 48.4% and 50.8%, respectively). Significant marrow toxicity (decrease in platelets) occurred in 3 patients ..<\/p>\n<p>In summary, from this study in which the Foundation participated, it can be deduced that the therapeutic vaccine TG4040 is effective in the treatment of hepatitis C. However, given the significant haematological toxicity that it produces, it will no longer be used in the treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"TG4040 is a modified Ankara vaccine virus that expresses the hepatitis C virus NS3, NS4 and NS5B proteins (therapeutic vaccine). The Foundation participated in a phase II clinical trial in patients with chronic hepatitis C.","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[622,624],"tags":[],"class_list":["post-1728","post","type-post","status-publish","format-standard","hentry","category-hepatitis-c-en","category-treatments"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.7 (Yoast SEO v23.7) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Efficacy of Immunotherapy with TG4040 in Chronic Hepatitis - Cl\u00ednica FEHV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Efficacy of Immunotherapy with TG4040 in Chronic Hepatitis\" \/>\n<meta property=\"og:description\" content=\"TG4040 is a modified Ankara vaccine virus that expresses the hepatitis C virus NS3, NS4 and NS5B proteins (therapeutic vaccine). The Foundation participated in a phase II clinical trial in patients with chronic hepatitis C.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/\" \/>\n<meta property=\"og:site_name\" content=\"Cl\u00ednica FEHV\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pages\/Fundacion%20Para%20el%20Estudio%20de%20las%20Hepatitis%20Virales\/228605694153917\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-08-23T18:34:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-08-23T18:34:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fehv.org\/wp-content\/uploads\/2018\/07\/medicamento_hepatitis_c_virus.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"612\" \/>\n\t<meta property=\"og:image:height\" content=\"340\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ifranco\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ifranco\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/\"},\"author\":{\"name\":\"ifranco\",\"@id\":\"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777\"},\"headline\":\"Efficacy of Immunotherapy with TG4040 in Chronic Hepatitis\",\"datePublished\":\"2018-08-23T18:34:27+00:00\",\"dateModified\":\"2018-08-23T18:34:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/\"},\"wordCount\":191,\"publisher\":{\"@id\":\"https:\/\/fehv.org\/#organization\"},\"articleSection\":[\"Hepatitis-C\",\"Treatments\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/\",\"url\":\"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/\",\"name\":\"Efficacy of Immunotherapy with TG4040 in Chronic Hepatitis - Cl\u00ednica FEHV\",\"isPartOf\":{\"@id\":\"https:\/\/fehv.org\/#website\"},\"datePublished\":\"2018-08-23T18:34:27+00:00\",\"dateModified\":\"2018-08-23T18:34:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/fehv.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Efficacy of Immunotherapy with TG4040 in Chronic Hepatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fehv.org\/#website\",\"url\":\"https:\/\/fehv.org\/\",\"name\":\"Cl\u00ednica FEHV\",\"description\":\"Web de la Cl\u00ednica de la Fundaci\u00f3n para el Estudio de las Hepatitis Virales\",\"publisher\":{\"@id\":\"https:\/\/fehv.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fehv.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fehv.org\/#organization\",\"name\":\"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV\",\"url\":\"https:\/\/fehv.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fehv.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png\",\"contentUrl\":\"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png\",\"width\":47,\"height\":73,\"caption\":\"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV\"},\"image\":{\"@id\":\"https:\/\/fehv.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/pages\/Fundacion Para el Estudio de las Hepatitis Virales\/228605694153917\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777\",\"name\":\"ifranco\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fehv.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa877054d0216c55e7104c50647e81a8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa877054d0216c55e7104c50647e81a8?s=96&d=mm&r=g\",\"caption\":\"ifranco\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Efficacy of Immunotherapy with TG4040 in Chronic Hepatitis - Cl\u00ednica FEHV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/","og_locale":"en_US","og_type":"article","og_title":"Efficacy of Immunotherapy with TG4040 in Chronic Hepatitis","og_description":"TG4040 is a modified Ankara vaccine virus that expresses the hepatitis C virus NS3, NS4 and NS5B proteins (therapeutic vaccine). The Foundation participated in a phase II clinical trial in patients with chronic hepatitis C.","og_url":"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/","og_site_name":"Cl\u00ednica FEHV","article_publisher":"https:\/\/www.facebook.com\/pages\/Fundacion%20Para%20el%20Estudio%20de%20las%20Hepatitis%20Virales\/228605694153917\/","article_published_time":"2018-08-23T18:34:27+00:00","article_modified_time":"2018-08-23T18:34:54+00:00","og_image":[{"width":612,"height":340,"url":"https:\/\/fehv.org\/wp-content\/uploads\/2018\/07\/medicamento_hepatitis_c_virus.jpeg","type":"image\/jpeg"}],"author":"ifranco","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ifranco","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/#article","isPartOf":{"@id":"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/"},"author":{"name":"ifranco","@id":"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777"},"headline":"Efficacy of Immunotherapy with TG4040 in Chronic Hepatitis","datePublished":"2018-08-23T18:34:27+00:00","dateModified":"2018-08-23T18:34:54+00:00","mainEntityOfPage":{"@id":"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/"},"wordCount":191,"publisher":{"@id":"https:\/\/fehv.org\/#organization"},"articleSection":["Hepatitis-C","Treatments"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/","url":"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/","name":"Efficacy of Immunotherapy with TG4040 in Chronic Hepatitis - Cl\u00ednica FEHV","isPartOf":{"@id":"https:\/\/fehv.org\/#website"},"datePublished":"2018-08-23T18:34:27+00:00","dateModified":"2018-08-23T18:34:54+00:00","breadcrumb":{"@id":"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fehv.org\/en\/efficacy-of-immunotherapy-with-tg4040-in-chronic-hepatitis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fehv.org\/en\/"},{"@type":"ListItem","position":2,"name":"Efficacy of Immunotherapy with TG4040 in Chronic Hepatitis"}]},{"@type":"WebSite","@id":"https:\/\/fehv.org\/#website","url":"https:\/\/fehv.org\/","name":"Cl\u00ednica FEHV","description":"Web de la Cl\u00ednica de la Fundaci\u00f3n para el Estudio de las Hepatitis Virales","publisher":{"@id":"https:\/\/fehv.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fehv.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fehv.org\/#organization","name":"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV","url":"https:\/\/fehv.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/#\/schema\/logo\/image\/","url":"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png","contentUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png","width":47,"height":73,"caption":"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV"},"image":{"@id":"https:\/\/fehv.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pages\/Fundacion Para el Estudio de las Hepatitis Virales\/228605694153917\/"]},{"@type":"Person","@id":"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777","name":"ifranco","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa877054d0216c55e7104c50647e81a8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa877054d0216c55e7104c50647e81a8?s=96&d=mm&r=g","caption":"ifranco"}}]}},"_links":{"self":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/1728"}],"collection":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/comments?post=1728"}],"version-history":[{"count":2,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/1728\/revisions"}],"predecessor-version":[{"id":1730,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/1728\/revisions\/1730"}],"wp:attachment":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/media?parent=1728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/categories?post=1728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/tags?post=1728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}